Full coverage
Hegseth Is Pushing Testosterone. The VA Has Already Struggled With the Treatment.
By Extra Extra Editorial
Cross-spectrum analysis, synthesized with AI from 2 sources · Updated
Pete Hegseth, the incoming Secretary of Defense, has advocated for increased testosterone replacement therapy in the military as part of a broader vision for a more physically and mentally resilient fighting force. This push comes as the Department of Veterans Affairs has faced documented challenges in safely managing testosterone treatment programs, including complications related to dosing, monitoring, and patient outcomes. The proposal raises questions about how widespread testosterone therapy would be implemented across military personnel and whether existing infrastructure could handle expanded access. Hegseth's framing emphasizes physical performance and readiness, while critics point to the VA's track record of struggling with the treatment's complexities and potential health risks.
Left-leaning coverage frames Hegseth's testosterone advocacy as a potentially risky policy proposal that ignores documented institutional failures. The Intercept emphasizes the VA's past struggles with testosterone treatment as a cautionary example, suggesting that expanding access without addressing systemic problems could harm service members. This framing treats the proposal skeptically, positioning it as ideology-driven rather than evidence-based.
Center-oriented coverage takes a more explanatory approach, providing context about testosterone replacement therapy itself—how it works, its potential benefits and risks, and what medical evidence shows. PBS NewsHour frames the story as an opportunity to educate viewers about the treatment while acknowledging Hegseth's stated goals, presenting the issue as a policy question requiring informed understanding of the underlying science and logistics.
Key Differences
- Left coverage emphasizes institutional failure and risk, while center coverage focuses on medical education and factual context about testosterone therapy itself.
- Right-leaning outlets are absent from coverage, meaning Hegseth's perspective and the case for his proposal receive no direct articulation in these reports.
- The framing differs between cautionary (left) and informational (center), with no counterbalancing advocacy perspective present.
How this story is being covered
Extra Extra has grouped 2 reports on this story from 2 news outlets across the political spectrum. By political lean, that breaks down as 1 left-leaning and 1 center sources.
Its coverage-diversity score of 63 out of 100 means the story is being reported across multiple parts of the spectrum, though the volume leans toward one side. Notably, no right-leaning outlet in our index has picked the story up yet — a right-side blind spot that often signals a topic resonating more with progressive audiences.
On reliability, 2 of the 2 rated outlets carry a high or mostly-factual reliability rating (A or B). Ratings are drawn from independent assessments and are meant to help you weigh each report, not to tell you which to trust.
Coverage of this story has developed over roughly 47 hours, so the perspectives below capture how the framing shifted as the story matured.
Below, the same story is laid out side by side as left, center, and right outlets reported it. Read across the columns and watch what changes: the headline emphasis, which facts lead, the adjectives, and what each side leaves out. The story itself rarely changes — the framing almost always does.
Outlets covering this story: The Intercept, PBS NewsHour.
Left(1)
Center(1)
Right(0)
Get this analysis in your inbox
The Daily Spectrum: one email, three perspectives on the day's biggest stories.
Free forever. Unsubscribe anytime. No spam.
New to comparing coverage? Start with our guides to reading the news critically.
Back to Compare